1799612-08-0

Basic information

• Product Name: 4-bromo-2-chloro-3-methylphenol
• CAS NO: 1799612-08-0
• Molecular Weight: 221.481
• Mol File: 1799612-08-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 257.6±35.0 °C(Predicted)
• Density: 1.674±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-bromo-2-chloro-3-methylphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-chloro-3-methylphenol(1799612-08-0)
• EPA Substance Registry System: 4-bromo-2-chloro-3-methylphenol(1799612-08-0)

Safety Data

• Hazardous Substances Data: 1799612-08-0(Hazardous Substances Data)

Upstream product

• 608-26-4 2-chloro-m-cresol 
• 97329-43-6 1-bromo-2-chloro-3-methyl-benzene 
• 3964-56-5 4-bromo-2-chlorophenol 
• 74-88-4 methyl iodide 

Relevant articles and documents

MCL1 INHIBITORS AND USES THEREOF

The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.

2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER

A compound of formula I (the variables are defined in the claims) or a pharmaceutically acceptable salt or solvate thereof, as an MCL-1 enzyme inhibitor for treating colon cancer, breast cancer, small-cell lung cancer, non-small- cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer. The present description discloses the synthesis of exemplary compounds as well as biological assays thereof (e.g. pages 55 to 114; paragraphs [00216] to [00304]; examples 1 to 33; tables A and 2). An exemplary compound is e.g. (2R)-2-{[(5Ra)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy]phenyl}-6-(4-fluorophenyl) py rrolo[2, l-f][l, 2, 4]triazin-4-yl]am ino}-3-(2-{[2-(2-methoxy phenyl) py rim idin-4-yl]methoxy} phenyl) propanoic acid (example 13) with e.g. 0.7 nM BIM_Ki in an cell free MCL-1 Bim affinity assay.

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).